Most Read Articles
5 days ago
Use of statin appears to reduce the risks of osteoporosis, hip fractures and vertebral fracture in patients newly diagnosed with a stroke, suggests a recent study.
2 days ago
Elderly adults using hypoglycaemic glucose-lowering drugs, such as insulin and glinides, have an excess risk of hospitalization for serious trauma, a recent study has found.
07 Oct 2018
Patients using long-acting opioids with immunosuppressive properties are at greater risk of developing serious infections compared with those using the nonimmunosuppressive opioid counterpart, according to a study.
5 days ago
Monitoring of adverse events is lower in ambulatory patients on amiodarone than in those on dofetilide, a recent study has found. Improving the monitoring of such agents may help reduce the risk of morbidity in this population.

Maintenance therapy with difluoromethylornithine safe, effective in high-risk neuroblastoma

6 days ago

Difluoromethylornithine (DFMO) maintenance medication in high-risk neuroblastoma (HRNB) patients is associated with better survival outcomes, a recent study has shown.

The study included HRNB patients with histologically confirmed disease who took maintenance DFMO to prevent relapse following completion of standard therapy (stratum 1; n=101; mean age 3.5 years; 56 percent male) or after salvage therapy for relapsed disease (stratum 2; n=39; mean age 3.2 years; 72 percent male).

Over a median follow-up period of 3.5 years, participants in stratum 1 demonstrated a mean 2-year event-free survival rate of 84.4±4 percent. Overall survival was likewise high at 97±2 percent. Survival rates remained high even in patients with high-risk features such as status of the MYCN gene.

In the subset of stratum 1 participants who were given DFMO after the completion of the Children’s Oncology Group antibody clinical trial, event-free and overall survival rates were also high (86±4 percent and 97±2 percent).

In stratum 2, the 2-year event-free and overall survival rates were low at 51±8 percent and 84±6 percent, respectively. These values were lower in patients with relapsed disease (35±11 percent and 80±9 percent, respectively) and higher in those with primary refractory disease (68±11 percent and 89±7 percent, respectively).

In terms of safety, no serious adverse events were reported. Majority (67 percent) of the patients reported no treatment-related adverse events. Grade 2–3 transaminitis was the most common adverse event, and none of the cases required suspension of the DFMO treatment.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
5 days ago
Use of statin appears to reduce the risks of osteoporosis, hip fractures and vertebral fracture in patients newly diagnosed with a stroke, suggests a recent study.
2 days ago
Elderly adults using hypoglycaemic glucose-lowering drugs, such as insulin and glinides, have an excess risk of hospitalization for serious trauma, a recent study has found.
07 Oct 2018
Patients using long-acting opioids with immunosuppressive properties are at greater risk of developing serious infections compared with those using the nonimmunosuppressive opioid counterpart, according to a study.
5 days ago
Monitoring of adverse events is lower in ambulatory patients on amiodarone than in those on dofetilide, a recent study has found. Improving the monitoring of such agents may help reduce the risk of morbidity in this population.